Altered expression of fibroblast activation protein-α (FAP) in colorectal adenoma-carcinoma sequence and in lymph node and liver metastases by Solano Iturri, Jon Danel et al.
 
www.aging-us.com 10337 AGING 
www.aging-us.com AGING 2020, Vol. 12, No. 11 
Research Paper 
Altered expression of fibroblast activation protein-α (FAP) in 
colorectal adenoma-carcinoma sequence and in lymph node and liver 
metastases 
 
Jon Danel Solano-Iturri1,2, Maider Beitia2,3,4, Peio Errarte2,4, Julio Calvete-Candenas5, María C. 
Etxezarraga2,6, Alberto Loizate7, Enrique Echevarria4, Iker Badiola8, Gorka Larrinaga2,3,4 
 
1Department of Anatomic Pathology, Cruces University Hospital, University of the Basque Country (UPV/EHU), 
Barakaldo, Bizkaia, Spain 
2BioCruces Health Research Institute, Barakaldo, Bizkaia, Spain 
3Department of Nursing, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, 
Bizkaia, Spain 
4Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, 
Bizkaia, Spain  
5Department of Oncology, University Hospital Puerta del Mar, Cádiz, Spain 
6Department of Anatomic Pathology, Basurto University Hospital, University of the Basque Country (UPV/EHU), 
Bilbao, Bizkaia, Spain 
7Department of Surgery, Basurto University Hospital, University of the Basque Country (UPV/EHU), Bilbao, Bizkaia, 
Spain 
8Department of Cell Biology and Histology, Faculty of Medicine and Nursing, University of the Basque Country 
(UPV/EHU), Leioa, Bizkaia, Spain 
 
Correspondence to: Gorka Larrinaga; email: gorka.larrinaga@ehu.es 
Keywords: colorectal carcinoma, fibroblast activation protein, cancer associated fibroblast, metastasis 
Received: January 30, 2020 Accepted: April 20, 2020  Published: May 19, 2020 
 
Copyright: Solano-Iturri et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 
License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original 




Colorectal cancer (CRC) is a major health problem in elderly people because of its high incidence and high 
mortality rate. Despite early screening programs, more than half of CRC patients are diagnosed at advanced 
stages. Fibroblast activation protein-α (FAP) expression in cancer-associated fibroblasts (CAFs) has been 
associated with a higher risk of metastases and poor survival. Here, we have analyzed the 
immunohistochemical expression of FAP in 41 adenoma-carcinoma sequences. In addition, FAP expression 
was analyzed individually and in combination with β-catenin (BCAT), CD44 and Cyclin-D1 expression in 
primary tumors and in their corresponding lymph node and liver metastases (n=294). Finally, soluble FAP 
(sFAP) levels in plasma from CRC patients (n=127) were also analyzed by ELISA. FAP was expressed only in 
CRC tissue and its expression level was found to be higher in tumors exhibiting deeper local invasion and 
poorer cancer cell differentiation. FAP and concomitant nuclear BCAT expression in cancer cells at the 
infiltrating front of primary tumors and in lymph node metastases was independently associated with 5- 
and 10-year cancer specific and disease-free survival. Moreover, lower sFAP levels correlated with poorer 
survival. These findings support the potential importance of FAP as a biomarker of CRC development and 
progression. 
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INTRODUCTION 
 
Colorectal cancer (CRC) is one of the most common 
malignancies in terms of incidence and the second 
leading cause of cancer deaths worldwide [1]. 
Despite the implementation of early screening 
programs in several countries, more than half of 
patients are diagnosed with advanced and metastatic 
disease (stages III-IV) [2]. Metastasis to liver and 
lung are the principal causes of death [2, 3]. 
Therefore, a better understanding of the biomolecular 
changes underlying colorectal cancer development 
and metastatic processes is necessary for the design 
of novel, more effective diagnostic, prognostic and 
therapeutic tools. 
 
Cancer development and progression rely not only on 
neoplastic cells themselves, but also on their interaction 
with other cells of the tumor microenvironment (TME), 
such as cancer-associated fibroblasts (CAFs) [4, 5]. 
These cells are the most ubiquitous elements of tumor 
stroma from epithelial cancers and have been proposed 
to be the “architects of cancer pathogenesis” [6] because 
of their participation in the acquisition of several 
hallmarks of cancer [4, 5]. 
 
During the neoplastic transformation of the colorectal 
epithelium, transforming tumor cells secrete different 
molecules responsible for fibroblast differentiation 
into CAFs; the integrity of the basal membrane is 
disrupted and local invasion of intestinal layers by 
cancer cells begins [8]. Detecting this early CRC 
invasion can be diagnostically difficult, both in small 
biopsy specimens and in adenoma tissues [9]. 
 
CAFs can induce tumor invasiveness and disease 
relapse by promoting the epithelial to mesenchymal 
transition (EMT) of CRC cells [7, 8], and are among 
the most influential cells for promoting the generation 
of cancer stem cell (CSC) subpopulations, which is 
highly associated with resistance to chemotherapy and 
radiotherapy [7, 8, 10]. Studies in xenograft models 
have also shown that CAFs have an important role in 
the development of pre-metastatic niches, in the 
nesting of cancer cells in distant organs and in the 
activation of these cells from their dormant state [8, 
11]. Moreover, the activation of CAFs has been 
associated with the size of CRC metastases in local 
lymph nodes [12]. For these reasons, the study of the 
role of CAFs in TME has become a “hot topic” in 
CRC research [7, 8]. 
 
A hallmark of the activation of CAFs is the cell 
surface expression of fibroblast activation protein-α 
(FAP), a serine protease with multifunctional 
properties which is also found in body fluids. This 
protein has been proposed to be a potential tumor 
biomarker [13–17], as its expression is more abundant 
in tumors with invasive phenotypes that are more 
likely to metastasize [18]. FAP has also been  
studied as a therapeutic target for CAF-targeted 
immunotherapies [19]. The relationship between FAP 
expression in CRC and poor clinical outcome has also 
been reported [20–22]. However, these studies have 
been performed using primary tumors and FAP 
expression in CRC metastases has to date not been 
characterized [18]. 
 
Thus, in this study, we have analyzed the 
immunohistochemical expression of FAP in a series of 
colorectal tumors, from adenomatous lesions to 
advanced primary CRCs, to local and distant 
metastases. We also analyzed the association between 
FAP expression in CRC tissues with proliferation, EMT 
and CSC marker expression such as Cyclin-D1, β-
catenin (BCAT) and CD44. Finally, soluble FAP was 





FAP expression and the gender and age of CRC 
patients 
 
The Rho Spearman test was conducted to assess if FAP 
protein expression varies according to the gender or age 
of the patients. Results showed no statistically 
significant differences (p>0.05 in all cases, not shown), 
allowing us to conclude that the sample has no gender 
or age bias. 
 
FAP expression throughout the adenoma-CRC 
sequence  
 
None of the tissues corresponding to uninvolved 
mucosa or adenomatous polyps showed any FAP 
protein expression (Chi-square test p<0.001). This 
protein was exclusively expressed in the stromal 
fibroblasts present in CRC tissues, where 68.3% of the 
analyzed CRC cases were classified as positive (Figure 
1A, 1B).  
 
FAP expression and histological subtypes of CRC 
 
We divided the histological subtypes into three 
groups: conventional adenocarcinoma (AdC), 
mucinous carcinoma (MuC) and signet ring cell 
carcinoma (SrcC). FAP expression varied according 
to histological subtype. Thus, AdCs showed 
significantly stronger FAP protein expression than 
MuC and SrcC at the infiltrating front (p<0.001). In 
local and distant metastases from AdCs, FAP 
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expression was higher than metastases from SrcCs 
(p<0.05 in both cases) (Figure 2A, 2B).  
 
Taking into consideration such differences, and to avoid 
bias, all subsequent analyses were conducted only in 
conventional adenocarcinoma (AdC), which conform 
the great majority of the cases. 
FAP expression along the conversion of primary 
tumors into metastases in AdC 
 
With the aim of exploring the role of FAP protein 
expression in CRC progression, we measured its 
expression along the four phases that represent the 




Figure 1. Immunohistochemical FAP staining along the adenomatous polyp-cancer sequence of CRC. (A) 68,3% of 
adenocarcinomas were positively stained. Uninvolved colorectal mucosa and adenomas were negative (x200). (B) FAP staining was scored as 
negative or positive. The scores were quantified in each tissue type and statistical significance of the FAP expression pattern among the 




Figure 2. Immunohistochemical FAP staining according to CRC histologic subtypes. (A) Higher percentage of positive staining was 
observed in conventional adenocarcinoma (AdC) with respect to mucinous (MuC) and signet ring cell carcinomas (SrcC) in the infiltrating 
front primary tumour (x200). (B) FAP staining intensity was scored as negative or positive. The scores were quantified in each histologic 
subtype and statistical significance was determined by Chi-Square test (*p<0.05; ***p<0.001). H&E: Hematoxylin and Eosin. FAP: Fibroblast 
activation protein-α. 
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infiltrating front of primary tumors, and in local and 
distant metastases (Figure 3). 
 
In primary tumors, we found overall higher FAP 
expression at the infiltrating front with respect to the 
tumor center (Chi-square test p=0.1). When primary and 
metastatic tissues were compared, FAP expression was 
significantly lower in both local and distant metastases 
(p<0.001 in all cases) with respect to the tumor center. 
However, no significant differences were found 
between these metastatic tissues (Figure 3A, 3B). 
 
Despite these differences, FAP expression in the 
primary tumor center and border positively correlated 
with FAP expression in both lymph nodes (Spearman 
Rho r=0.166, p=0.028; and r=0.24, p=0.002; 
respectively) and distant liver metastases (r=0.279, 
p=0.007; and r=0.256; p=0.016 respectively). Thus, the 
higher the expression of FAP in primary tumors, the 
higher the expression of this protein in metastases. 
FAP expression and CRC aggressiveness 
 
In order to study the impact of FAP expression on CRC 
prognosis, we stratified its expression in primary 
conventional adenocarcinoma tissues with a range of 
clinical parameters tightly related to CRC aggressiveness 
such as histological grade, local invasion (pT), number of 
affected lymph nodes (N), presence/absence of metastasis 
(M) and the stage (TNM system). 
 
Results are presented in Table 1. We observed 
differences between different histological grades, where 
tissues corresponding to grade 3 (high grade) showed a 
higher percentage of FAP staining than tissues 
corresponding to grades 1 and 2 (low grades). These 
differences were statistically significant at the 
infiltrating front (p=0.018). 
 
Regarding local invasion (pT), FAP expression in the 




Figure 3. Immunohistochemical FAP expression in primary (centre and border) and corresponding metastatic (lymph node 
and liver) tissues of conventional adenocarcinomas (AdCs). (A) Higher percentage of positive staining was observed in primary 
tumours than in metastases (x200). (B) FAP staining intensity was scored as negative or positive. The scores were quantified in each tissue 
type and statistical significance of FAP expression pattern among the different tissues was determined by Chi-Square test (***p<0.001). H&E: 
Hematoxylin and Eosin staining. FAP: Fibroblast activation protein-α. 
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Table 1. FAP protein expression pattern according to the different pathological parameters in the center and the 
infiltrating front of the analyzed primary tumors.  

















1-2 42.3 57.7 36.1 63.9 
3 27.3 72.7 15.2 84.8 
pT1 - pT2 69.2 30.8 30.8 69.2 
pT3 44 56 35.1 64.9 
pT4 25 75 28.6 71.4 
N0 47.2 52.8 41.7 58.3 
N1 42.6 57.4 29.9 70.1 
N2 33.7 66.3 33.3 66.7 
M0 41.4 58.6 35.1 64.9 
M1 38.3 61.7 30.1 69.9 
I-II 54.2 45.8 45.8 54.2 
III 35.8 61.5 32.7 67.3 
IV 38.3 61.7 30.1 69.9 
Statistical significance was determined by Chi-square test. Statistically significant values are highlighted in bold. 
 
infiltrated the large intestine wall. Thus, FAP 
expression was significantly higher in tumors invading 
the visceral peritoneum or other adjacent organs (pT4) 
than in pT1-2 (p=0.002) and pT3 (p=0.009) 
adenocarcinomas.  
 
FAP expression at the infiltrating front showed high 
percentages of positivity in all the pT stages (from 
64.9% to 71.4%). In addition, when comparing the 
center and front from tumors invading the submucosa 
and muscularis propria (pT1-2), we found FAP 
expression to be two-fold higher at the infiltrating front 
(30.8% vs. 69.2% positive cases respectively; p=0.05).   
 
When data were stratified according to N, M or stage, 
no statistically significant differences were observed 
between the different groups. 
 
FAP expression in terms of the cancer-specific (CSS) 
and disease-free survival (DFS) of AdC patients 
 
We aimed to define the role FAP might play in CSS 
and DFS of CRC affected patients at both 5 and 10 
years from diagnosis time. The average follow-up of 
the AdC series was 45 months ranging from 0 to 184 
months. 
 
Results showed no statistically significant relationship 
between FAP expression from primary and metastatic 
tissues and patients’ CSS and DFS, neither at 5 nor at 
10 years follow-up (Log-rank p>0.05) (Supplementary 
Table 1A). 
Expression of FAP in combination with BCAT, 
CD44 and Cyclin-D1 stratified by risk of metastases, 
CSS and DFS  
 
Data from FAP expression in primary and metastatic 
tissues were also analyzed in combination with the 
expression of BCAT, CD44 and Cyclin-D1 
(Supplementary Figure 1). Our objectives were: 1) to 
characterize the association between the combined 
expression of these biomarkers in primary tumors and 
local lymph node metastases and the onset of distant 
metastases; and 2) to evaluate how these double 
combinations can predict 5- and 10-year CSS and DFS 
of conventional adenocarcinoma patients.  
 
Multiple logistic regression analyses were performed to 
carry out the first objective. Significant results were 
obtained when we studied simultaneous expression of 
FAP (FAP(+)) in CAFs and β-catenin in the nucleus of 
CRC cells (BCAT(N)). Table 2 shows that the 
combined expression of these two biomarkers at the 
infiltrating front of the primary tumor (as well as pT) 
was independently associated with metastasis 
occurrence.  
 
In both the tumor center and in local metastasis, 
FAP(+)/BCAT(N) was not associated with metastasis 
occurrence. We also did not find any association 
between metastasis onset and the expression of both 
FAP(+)/CD44 high and FAP(+)/Cyclin-D1 high 
staining in primary tumor and in metastatic lymph node 
tissues (Supplementary Table 2). 
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Table 2. Predictive model (multiple logistic regression model) according to metastatic status of CRC patients at 
diagnosis time. 
 Infiltrating front 
Variables p value B ExpB Inferior Superior 
Grade 0.745 -0.085 0.919 0.552 1.529 
pT 0.005 0.793 2.209 1.270 3.842 
N 0.349 0.203 1.225 0.801 1.871 
FAP(+)/BCAT(N) 0.026 0.857 2.355 1.107 5.011 
pT 0.001 0.865 2.374 1.396 4.039 
FAP(+)/BCAT(N) 0.022 0.878 2.405 1.132 5.108 
Selected independent variables were FAP positive and nuclear BCAT in tumor front, grade, local (pT) and lymph node invasion 
(N). A stepwise selection procedure (backward Wald method) was used to select the final optimal model. ExpB with 
confidence interval (CI) is also included. According to the Omnibus test, the model was statistically significant (p=0,002). 
Hosmer–Lemeshow test (p=0,7). R2 Nagelkerke (p=0,1). Statistically significant values are highlighted in bold. 
 
With regard to the second objective, the 
FAP(+)/BCAT(N) staining combination was associated 
with worse 5- and 10-year CSS and DFS. Statistically 
significant results were found at the infiltrating front of 
the primary tumor for CSS prediction and at the 
infiltrating front and in local lymph node metastasis for 
DFS prediction (Figure 4). 
 
The Log-rank test did not reveal any significant 
association between the other biomarker combinations 
and patients’ CSS and DFS (Supplementary Table 3). 
 
Additionally, we also performed an individual 
analysis of BCAT and patients’ survival, in order to 
ascertain if the combination of FAP and BCAT 
provides higher predictive value for survival than the 
individual analysis of each marker. Nuclear 
expression of BCAT in tumor cells from primary 
tumor tissues and in metastases was not found to show 
significant association with the CSS and DFS of AdC 
patients (Supplementary Table 1B). 
 
Univariate (Supplementary Tables 4 and 5) and 
multivariate analyses (Table 3) were performed to test 
whether the FAP(+)/BCAT(N) staining combination 
at the tumor front and in lymph node metastasis was 
an independent prognostic factor predicting CSS  
and DFS. Thus, the Cox regression model showed that 
this protein combination at the infiltrating front of the 
primary tumor was an independent prognostic  
factor for 5-year CSS, together with pT, metastasis 
and tumor grade. Expression of FAP(+)/BCAT(N) 
staining combination at the infiltrating front and in 
lymph node metastasis was also found to be an 
independent prognostic factor for 5-year DFS, 
together with local invasion (pT) (Table 3). Similar 
significant results were obtained for the prediction of 
10-year CSS and DFS (Supplementary Tables 4,  
5 and 6). 
Soluble FAP in CRC patient plasma 
 
Soluble FAP (sFAP) levels were measured in plasma 
samples of 127 CRC patients and 50 healthy subjects. 
Table 4 illustrates the clinical and pathological 
parameters of the CRC patients. All histological 
subtypes were conventional adenocarcinomas (AdC). 
sFAP concentration values followed a normal 
distribution as indicated by the Kolmogorov-Smirnov 
test (p>0.05) and there were no age or gender biases 
affecting sFAP plasma concentration (Pearson test, 
p>0.05 in both cases). AdC patients had lower sFAP 
plasma levels (58.6 ng/mL) than control subjects (92.2 
ng/mL) (T Student, p<0.0001) (Figure 5A).  
 
When sFAP levels were stratified according to several 
parameters associated with CRC aggressiveness, sFAP 
levels were found to be significantly lower in patients 
with lymphatic vessel invasion (L) than the ones 
without invasion (p<0.05). A similar trend was 
observed in patients diagnosed with higher grade, pT 
and pN, but these results were not statistically 
significant (Table 4). Besides, sFAP levels were 
inversely correlated with tumor size (Pearson test, r= -
0.291, p=0.001). 
 
Cut-off values of sFAP for overall survival analyses 
were obtained by a Classification and Regression Tree 
(CRT). A sFAP value of 30,11 ng/mL determined two 
nodes with significant differences in the percentage of 
alive patients, 30% vs 74% (p=0.03) (Supplementary 
Figure 2). Kaplan-Meier curves showed that CRC 
patients with low soluble FAP levels (≤30.11 ng/ml) 
presented worse overall survival than patients with 
soluble FAP levels above this cut-off (Log-Rank test 
p≤0.001) (Figure 5B). 
 
Univariate (Supplementary Table 7) and multivariate 
Cox regression analyses (Table 5) revealed that plasma 
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sFAP with this cut-off value, histological grade, distant 
metastasis and vascular invasion are independent 
prognostic factors for the overall survival (OS) of AdC 




The first relevant result of this study was observed in 
colorectal adenoma-carcinoma sequence. FAP was only 
expressed by fibroblasts in cancerous tissues, in 
agreement with the previous work of Henriksson et al. 
[23]. These authors demonstrated in vitro that medium 
conditioned by CRC cells, but not by adenoma cells, 
induces FAP expression in CAFs, suggesting that FAP 
may be a useful diagnostic marker for early CRC 
invasion [23]. Thus, FAP expression may be specific to 
CAFs surrounding cancer cells that infiltrate mucosa, 
but this hypothesis would need to be substantiated with 
further studies of a series of adenomatous polyps with 
high grade intraepithelial dysplasia. 
FAP expression was lower in CAFs from MuC and SrCC 
than in conventional adenocarcinoma (AdC). The lower 
staining could be due to the typical large areas of 
mucinous degeneration of these tumors that leads to 
lower collagenous stromal matrix [24], which is the 
habitat of CAFs. In keeping with this result, it was 
reported very recently that FAP expression is lower in 
CRC tumors with low stroma amounts [25]. Therefore, 
these histotype-related differences in staining patterns 
should be taken into account for the 
immunohistochemical evaluation of FAP in CRC tissues.  
 
Tumor border configuration has been proposed as an 
important histomorphological variable for CRC 
prognosis [26, 27]. In the margins of the tumor, single 
CRC cells or clusters with morphological changes of 
epithelial to mesenchymal transition (EMT) are typical 
[26, 27]. In addition, host-related factors also influence 
the invasive behavior of these margins and, therefore, 




Figure 4. Immunohistochemical FAP and nuclear BCAT staining in the infiltrating front and in lymph node metastasis. (A) FAP 
was expressed in CAFs that penetrated within the body of lymphatic nodes. Nuclear and adjacent cytoplasmic BCAT staining represents BCAT 
signalling translocation from membrane to nucleus (x200). (B, C) Kaplan-Meier curves and univariate Log-rank test showed that simultaneous 
expression of FAP in CAFs and nuclear BCAT in AdC cells from the infiltrating front significantly associated with worse 5-year cancer-specific 
(CSS) and disease-free (DFS) survival of AdC patients. (D) The same combination in lymph node metastases was significantly associated to 5-
year DFS. 
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Table 3A. Predictive model (Cox regression) for 5-year cancer-specific survival (CSS) prediction in AdC patients. 
5-year CSS Variables p value ExpB Inferior Superior 
FAP(+)/BCAT(N) 
tumor front 
3.5x10-4 1.20 1.09 1.33 
Grade 0.007 1.49 1.11 1.99 
pT 5.2x10-5 1.89 1.39 2.56 
N 0.96 0.99 0.78 1.26 
M 7.3x10-5 1.88 1.38 2.57 
FAP(+)/BCAT(N) 
tumor front 
3.4x10-4 1.20 1.09 1.33 
Grade 0.006 1.49 1.12 1.97 
pT 2.6x10-5 1.88 1.40 2.53 
M 7.2x10-5 1.88 1.38 2.57 
Selected independent variables were: FAP(+)/BCAT(N) expression in the primary tumor’s infiltrating front, histologic grade, 
local invasion (pT), lymph node (N) and distant (M) metastases. ExpB with confidence interval (CI) is also included. Statistically 
significant values are highlighted in bold. 
 
Table 3B. Predictive model (Cox regression) for 5-year disease-free survival (DFS) prediction in AdC patients. 
  Tumor front Local metastasis 
5-year DFS Variables p value ExpB Inferior Superior p value ExpB Inferior Superior 
FAP(+)/BCAT(N) 0.011 1.18 1.04 1.34 0.002 1.29 1.09 1.52 
Grade 0.174 1.29 0.89 1.86 0.730 1.08 0.70 1.66 
pT 0.018 1.59 1.08 2.33 0.009 1.75 1.15 2.67 
N 0.723 1.05 0.79 1.41 0.408 1.21 0.77 1.91 
FAP(+)/BCAT(N) 0.016 1.17 1.03 1.33 0.001 1.31 1.11 1.54 
pT 0.008 1.65 1.14 2.39 0.005 1.80 1.19 2.73 
Selected independent variables were: FAP(+)/BCAT(N) expression in the primary tumor’s infiltrating front and in the lymph 
node metastasis, histologic grade, local invasion (pT), lymph node (N) and distant (M) metastases. ExpB with confidence 
interval (CI) is also included. Statistically significant values are highlighted in bold. 
 
Table 4. Soluble FAP (sFAP) levels according to clinical and pathological parameters of CRC patients.  
Patients’ clinical and pathological data (n=127) Average (%) 
sFAP levels 
(ng/ml) 
 p value 
Follow-up months (range)  50 (3-83)   
Age average (range)  70 (34-93)   
Male 92 (72%) 57.9 
Female 35 (28%) 60.1 
G1 6 (5%) 57.4  
G2 118 (93%) 58.7 0,92 
G3 3 (2%) 53.7  
pT2 32 (25%) 60.3  
pT3 85 (67%) 58.9 0.41 
pT4  10 (8%) 50.1  
N0 75 (59%) 60.2  
N1  41 (32%) 57.4 0.41 
N2 11 (9%) 51.4  
M0 123 58.4 
M1 4 61.9 
I 26 (20%) 56.9  
II 48 (38%) 62.9  
III 49 (39%) 54.8 0.29 
IV 4 (3%) 61.9  
No 110 (87%) 58.6 
Yes 17 (13%) 58.3 
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Lymphatic vessel invasion (L) 
No 103 (81%) 60.6 
0.03 
Yes 24 (19%) 49.8 
No 108 (85%) 58.5 
Yes 19 (15%) 58.7 
T Student test and ANOVA test were used for the comparison between two or more than two groups respectively. Significant 
p values are highlighted in bold.  
 
 
From a molecular perspective, the translocation of 
BCAT to the nucleus is a key event which confers 
invasive properties on CRC cells. There, it activates 
target genes that encode markers such as CD44 and 
cyclin-D1, inducing EMT, CSC-like phenotype and cell 
proliferation [29, 30]. These markers have been found 
to be associated with a poorer prognosis of CRC 
patients [30–31]. In addition, functional studies have 
demonstrated that FAP expression in the membrane of 
CAFs induces BCAT-related pathway phenomena in 
CRC cells [7, 33], which can explain in part the impact 
of FAP in CRC development and prognosis [20–22]. 
 
Taking all this evidence into account, we decided to 
analyze FAP expression individually and in 
combination with these markers in the tumor center and 
at the infiltrating front of primary AdCs. Thus, the 
tumor front showed high FAP expression in high 
histological grade tumors and in all the stages of local 
invasion (pT). Furthermore, FAP positivity in CAFs and 
concomitant nuclear expression of BCAT in neoplastic 
cells from the tumor margins were independently 
associated with a higher risk of metastasis and with 
worse CSS and DFS of conventional adenocarcinoma 
patients. These results suggest that the impact of FAP 
on the aggressive behavior of primary AdCs takes place 
mainly at the infiltrating front, and that this expression 
may be associated with BCAT-related phenomena in 
tumor cells [7, 33].  
 
These findings also illustrate the importance of the 
combined analyses of immunohistochemical results, 
which can yield relevant information not revealed by 
individual analyses. In this regard, Herrera et al. [22] 
demonstrated that the combination of M2 macrophage 
and CAF markers such as FAP identifies groups of 
advanced CRC patients with significant differences in 
the progression of the disease.   
 
We observed significant differences in FAP expression 
between primary tumors and their corresponding local 
and distant metastases. Nevertheless, there was a 
positive correlation between FAP expression in both 
locations, reminiscent of our previous findings in renal 
cancer [34]. FAP was found to be expressed in CAFs 
that penetrated into the body of lymph nodes, which is a 
sign of fibroblast activation associated with cancer cell 
colonization [12]. Moreover, concomitant FAP/nuclear 
BCAT expression in lymph node metastases was 





Figure 5. Soluble FAP (sFAP) plasmatic levels in AdC patients (n=127) and in healthy subjects (n=50). (A) sFAP levels were 
significantly lower in AdC patients than in controls (T Student, p<0.0001). (B) sFAP levels below 30,11 ng/mL were significantly associated 
with worse overall survival of AdC patients (Log-rank test, p=0.001).  
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Table 5. Predictive model (Cox regression) for 5-year overall survival (OS) prediction in AdC patients.  
Variables p value B ExpB Inferior Superior 
Grade 0.044 1.7 5.475 1.050 28.564 
pT 0.355 0.35 1.414 0.678 2.951 
N 0.264 0.3 1.353 0.796 2.300 
M 0.152 0.99 2.708 0.694 10.574 
V 0.100 0.69 2.008 0.875 4.609 
Pn 0.261 0.43 1.551 0.721 3.337 
Soluble FAP 0.046 -1.03 0.356 0.129 0.983 
Final Step of Wald Method      
Grade 0.001 2.52 12.474 2.854 54.527 
M 0.007 1.67 5.326 1.579 17.969 
V 0.013 0.97 2.653 1.229 5.728 
Soluble FAP 0.001 -1.42 0.243 0.104 0.565 
Selected independent variables were: soluble FAP, histologic grade, local invasion (pT), lymph node (N) and distant (M) 
metastases, and vascular (V) and perineural (Pn) invasion. ExpB with confidence interval (CI) is also included. Statistically 
significant values are highlighted in bold. 
 
It is known that CAFs from primary and metastatic 
sites can have different origins and phenotypes [11]. 
However, increasing evidence has shown that CAFs 
also circulate together with cancer cells, growth factors 
and exosomes from the primary site to distant organs 
during the metastatic process [35, 36]. This close 
communication between primary and secondary sites 
influences the progression of metastasis and the 
outcome of patients [11, 35–37]. Further studies will be 
necessary to clarify if the present findings are 
associated with the coordinated interaction of primary 
and distant sites or whether they represent independent 
phenomena.   
 
FAP has been mainly described in activated fibroblasts 
from cancer, chronic inflammatory and fibrotic lesions 
[17, 18]. Thus, higher sFAP levels would be expected in 
cancer patients in comparison with healthy subjects. 
However, we found that plasma samples from 
conventional adenocarcinoma patients had lower levels 
of the soluble fraction of FAP (sFAP) than those found 
in control subjects. Furthermore, lower sFAP levels 
were found to correlate with higher tumor size and 
invasion of lymphatic vessels, and independently 
associated with worse overall survival. A number of 
studies in several cancers showed similarly surprisingly 
reduced levels of sFAP associated with the cancer state 
[14–16]. Higher levels in healthy subjects indicates that 
sFAP may not be produced by the tumor tissues. 
Indeed, it has recently been reported that skeletal 
muscle, liver and bone marrow may be physiological 
sources of sFAP [16]. Lower sFAP levels in 
pathological conditions may reflect a systemic reaction 
to the presence of a developing tumor, a phenomenon 
comparable to decreased plasma level of negative acute-
phase proteins seen in inflammatory processes [15, 16, 
38]. Similarly, paradoxical results have also been 
reported for other peptidases in CRC [39, 40], 
underlining the need for further analyses, since it will be 
vital to ascertain the origin of plasma peptidases before 
they can be considered to be reliable biomarkers for 
liquid biopsies of CRC patients. 
 
In summary, the present findings corroborate the 
potential usefulness of FAP as a biomarker of CRC 
development and progression. Further studies will be 
necessary to contribute to a more detailed understanding 
of the role of FAP in cross-communications between 
cells of TME from primary and metastatic tumors. 
Since CRC represents a major health problem in 
developed countries [1], the importance of such studies 
which will contribute to the design of more effective 
diagnostic, prognostic and therapeutic tools, cannot be 
underestimated. 
 
MATERIALS AND METHODS 
 
The authors declare that all the experiments carried out 
in this study comply with the current Spanish and 
European Union legal regulations. Samples and data 
from patients included in this study were provided by 
the Basque Biobank for Research-OEHUN 
(https://www.biobancovasco.org). All patients were 
informed about the potential use for research of their 
surgically resected tissues, and manifested their consent 
by signing a specific document approved by the Ethical  
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Table 6. Clinical and pathological parameters of CRC patients for the immunohistochemical analysis of FAP protein 
expression.  




Age average (range)  70 (29-93) 
Follow-up months (range)  44 (0-188) 
Male 203 (69%) 
Female 91 (31%) 
Conventional Adenocarcinoma (AdC) 231 (79%) 
Mucinous carcinoma (MuC) 50 (17%) 
Signet ring cell carcinoma (SrcC) 13 (4%) 
G1 37 (13%) 
G2 161 (55%) 
G3 95 (32%) 
pT1 2 (<1%) 
pT2 13 (4%) 
pT3 178 (61%) 
pT4  101 (34%) 
N0 47 (16%) 
N1  130 (44%) 
N2 117 (40%) 
M0 182 (62%) 
M1 112 (38%) 
I 7 (2%) 
II 25 (9%) 
III 150 (51%) 
IV 112 (38%) 
 
and Scientific Committees of the Basque Country 





Three groups of samples were used in this research: 1) 
primary (n=294) and metastatic [(lymph node, n=227) 
and hepatic metastases, n=119)] tissues from 294 
patients diagnosed with advanced CRC were 
immunohistochemically analyzed; Table 6 summarizes 
the clinical and pathological characteristics of these 
patients; 2) a series of normal colonic mucosa, adenomas 
with low grade dysplasia and adenocarcinomas from the 
same patients (n=41) was used to 
immunohistochemically analyze the polyp-CRC 
sequence; and 3) plasma samples from 127 CRC patients 
and from 50 healthy subjects (see characteristics in 
Table 4) were used for the determination of the 
concentration of the soluble fraction of FAP.  
Immunohistochemistry 
 
Formalin-fixed and paraffin-embedded tissues were 
immunostained with antibodies specific for FAP (1:70 
dilution, Ab53066 Abcam), BCAT (Ready to use, 760-
4242, Roche-Ventana), CD44 (Ready to use, 790-4537, 
Roche-Ventana) and Cyclin-D1 (Ready to use, sc-718, 
Santa Cruz biotechnology). 
 
The immunostaining process was performed following 
routine methods in an automatic immunostainer 
(DakoAutostainer Plus, Dako-Agilent). Briefly, antigen 
retrieval was carried out in low pH buffer (K8005, 
Dako) for 20 minutes at 95ºC. The samples were 
incubated with the primary antibody for 50 minutes at 
room temperature. Then, the primary antibody was 
washed and samples were incubated for 20 minutes with 
secondary anti-rabbit antibody (K8021, Dako). The 
EnVision-Flex detection system together with a HRP 
enzyme labelled polymer (SM802, Dako) was used. The 
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presence of bound HRP-labeled secondary antibody was 
visualized with diaminobenzidine (DAB) solution 
(DM827, Dako) followed by counterstaining with 
hematoxylin (K8008, Dako).  
 
For staining evaluation, slides were reviewed under 
light microscopy. For FAP evaluation stromal staining 
was scored as negative, +, ++ and +++ according to 
the semi-quantitative scale described by Henry et al 
[20]. Negative/ + and ++/+++ levels were grouped in 
order to compare no/weak (≤ 10% stromal cells) with 
moderate/high (>10% stromal cells) staining groups 
[20]. Membranous staining of BCAT was interpreted 
as normal, and nuclear staining was considered 
translocational expression [41]. CD44 and Cyclin-D1 
staining was scored as negative, +, ++ and +++ 
attending not only to expression in neoplastic 
epithelial cells but also to non-immune stromal cells. 
For statistical purposes two groups of cases were 
defined in terms of negative/ + (low) and ++/+++ 
(high) expression levels [42–45]. 
 
The specimens were independently evaluated by two 
observers and discordant cases were jointly reviewed 




In order to determine the levels of soluble FAP, the 
sFAPDuoSet ELISA kit (R&D Systems, DY3715) 
was used [46, 47]. 100 µl of standards, reagent blank 
and plasma samples (1/100 dilution) were plated into 
a 96-well plate and incubated overnight at 4ºC. Wells 
were washed 4 times and 100 µl of labelled FAP 
antibody was added (except to the blank) and 
incubated for 1 hour at 4ºC. Then, wells were washed 
5 times and 100 µl of chromogen was added and 
incubated for 30 minutes at room temperature. 100ul 
of stop solution was added to each well and 





SPSS® 24.0 software was used for the statistical 
analysis.  
 
A Kolmogorov-Smirnov test was used to determine 
whether data obtained from tissue and plasma samples 
followed or not a normal distribution. Based on this 
information, data were analyzed with parametric or non-
parametric tests.  
 
We performed Pearson and Spearman Rho tests to 
evaluate the correlation between FAP expression and 
patient age and gender, and to correlate FAP 
expression from primary tumors and metastases. T-
Student and ANOVA tests were used to compare 
plasmatic FAP levels between two groups or more 
(respectively). Chi-square (χ2) test was used to analyze 
the categorical FAP expression (negative/positive) 
throughout the adenoma-CRC sequence, and the 
association with tissue FAP expression depending on 
pathological variables.  
 
To perform cancer-specific survival (CSS) and disease-
free survival (DFS) analyses, groups were created by 
cut-off points following different methods: for plasma 
analysis of FAP, a classification and regression tree 
(CRT) method was employed. For tissue analyses, cut-
off points were based on categorical expression of FAP 
(negative vs. positive). We also created groups 
combining data from FAP expression with β-catenin, 
CD44 and cyclin-D1 expression in CRC tissues. The 
following categorical groups of two markers were 
created (see Supplementary Figure 1): 1) FAP positive 
and nuclear β-catenin vs. rest of combination options 
between these two markers; 2) FAP positive and high 
CD44 vs. the rest, and 3) FAP positive and high Cyclin-
D1 vs. the rest. 
 
Kaplan-Meier curves and log-rank tests were performed 
to evaluate the association between the above-described 
groups and the CSS and DFS of CRC patients. Finally, 
multivariate analyses were used to test the independent 
effects of FAP expression (alone or combined with 
three other markers) and clinical and pathological 
variables on CSS and DFS (by Cox regression model) 
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performed the experiments. GL, EE and IB analyzed the 
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Supplementary Figure 1. (A) Images of immunohistochemical stains of FAP, BCAT, CD44 and Cyclin-D1. It is illustrated the entire spectrum 
of immunohistochemical results obtained in the different anatomical locations studied throughout the evolution AdC (primary tumour 
centre, infiltrative front, lymph node metastasis and distant liver metastasis). (B) Different combinations of TME immunohistochemical 
markers. The relationship between FAP+ / nuclear BCAT, FAP+ / CD44 high and FAP+ / Cyclin D1 high regarding to the rest of combinations in 
each pair of markers was studied. Data from tumour centre, infiltrating front and lymph node metastases were combined. 
  
 









Supplementary Figure 2. Classification and Regression Tree (CRT). A sFAP value of 30,11 ng/mL determined two nodes with 
significant differences in the percentage of alive patients (p=0.03). 
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Supplementary Tables 
 
Supplementary Table 1A. Log-rank test results of the association between FAP expression in primary tumors and 











Tumor Center 0.71 0.94 0.91 0.93 
Infiltrating front 0.46 0.32 0.72 0.71 
Local metastasis 0.86 0.88 0.25 0.22 
Distant metastasis 0.49 0.45 0.56 0.67 
 
Supplementary Table 1B. Log-rank test results of the association between BCAT expression (membrane/cytoplasmic 











Tumor Center 0.93 0.69 0.6 0.49 
Infiltrating front 0.08 0.45 0.08 0.24 
Local metastasis 0.37 0.9 0.71 0.81 
Distant metastasis 0.21 0.33 0.58 0.52 
 
Supplementary Table 2A. Multiple Logistic Regression Model according to metastatic status of CRC patients at 
diagnosis time: FAP positive and nuclear BCAT in tumor center.  
  Tumor center 
 Variables p value B ExpB Inf Sup 
 Grade 0.58 -0.14 0.86 0.52 1.45 
 pT 0.001 0.92 2.5 1.43 4.37 
 N 0.3 0.23 1.25 0.82 1.92 
 FAP(+)/BCAT(N) 0.24 -0.14 0.87 0.69 1.09 
ExpB and confidence interval (CI) is included. According to the Omnibus test, the model was statistically significant (p=0.003). 
Hosmer–Lemersow test (p=0.66). R2 Nagelkerke (p=0.09). Statistically significant values are highlighted in bold. 
 
Supplementary Table 2B. Multiple Logistic Regression Model according to metastatic status of CRC patients at 
diagnosis time: FAP positive and nuclear BCAT in lymph node local metastasis.  
 Local metastasis 
Variables p value B ExpB Inferior Superior 
Grade 0.79 -0.07 0.93 0.53 1.62 
pT 0.04 0.65 1.92 1.04 3.54 
N 0.16 0.44 1.55 0.84 2.87 
FAP(+)/CD44 0.45 -0.11 0.89 0.66 1.2 
ExpB and confidence interval (CI) is included. According to the Omnibus test, the model was not statistically significant 




www.aging-us.com 10355 AGING 
Supplementary Table 2C. Multiple Logistic Regression Model according to metastatic status of CRC patients at 
diagnosis time: FAP positive and high staining of CD44 in tumor center.  
 Tumor Center 
Variables p value B ExpB Inferior Superior 
Grade 0.38 -0.22 0.79 0.48 1.33 
pT 0.002 0.87 2.38 1.38 4.12 
N 0.26 0.24 1.27 0.84 1.95 
FAP(+)/CD44 0.46 -0.57 0.94 0.81 1.09 
ExpB and confidence interval (CI) is included. According to the Omnibus test, the model was statistically significant (p=0.004). 
Hosmer–Lemersow test (p=0.82). R2 Nagelkerke (p=0.09). Statistically significant values are highlighted in bold. 
 
 
Supplementary Table 2D. Multiple Logistic Regression Model according to metastatic status of CRC patients at 
diagnosis time: FAP positive and high staining of CD44 in the infiltration front.  
 Infiltrating Front 
Variables p value B ExpB Inferior Superior 
Grade 0.54 -0.16 0.85 0.5 1.44 
pT 0.001 0.96 2.62 1.5 4.57 
N 0.48 0.15 1.17 0.76 1.79 
FAP(+)/CD44 0.24 0.11 1.11 0.93 1.33 
ExpB and confidence interval (CI) is included. According to the Omnibus test, the model was statistically significant (p=0.003). 
Hosmer–Lemersow test (p=0.89). R2 Nagelkerke (p=0.1). Statistically significant values are highlighted in bold. 
 
Supplementary Table 2E. Multiple Logistic Regression Model according to metastatic status of CRC patients at 
diagnosis time: FAP positive and high staining of CD44 in local lymph node metastasis. 
 Local metastasis 
Variables p value B ExpB Inferior Superior 
Grade 0.54 -0.17 0.84 0.48 1.46 
pT 0.06 0.57 1.77 0.97 3.23 
N 0.18 0.41 1.51 0.82 2.78 
FAP(+)/CD44 0.97 0.01 1.01 0.8 1.25 
ExpB and confidence interval (CI) is included. According to the Omnibus test, the model was statistically significant (p=0.003). 
Hosmer–Lemershow test (p=0.89). R2 Nagelkerke (p=0.1). 
 
Supplementary Table 2F. Multiple Logistic Regression Model according to metastatic status of CRC patients at 
diagnosis time: FAP positive and high staining of Cyclin-D1 in the tumor center.  
 Tumor center 
Variables p value B ExpB Inferior Superior 
Grade 0.39 -0.22 0.80 0.48 1.33 
pT 0.002 0.86 2.37 1.37 4.11 
N 0.22 0.26 1.30 0.85 1.99 
FAP(+)/Cyclin-D1 0.27 0.08 1.09 0.94 1.26 
ExpB and confidence interval (CI) is included. According to the Omnibus test, the model was statistically significant (p=0.002). 
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Supplementary Table 2G. Multiple Logistic Regression Model according to metastatic status of CRC patients at 
diagnosis time: FAP positive and high staining of Cyclin-D1 in the infiltration front.  
 Infiltrating front 
Variables p value B OR Inferior Superior 
Grade 0.425 -0.21 0.81 0.49 1.35 
pT 0.003 0.83 2.29 1.33 3.96 
N 0.223 0.27 1.31 0.85 2.02 
FAP(+)/Cyclin-D1 0.261 0.08 1.09 0.94 1.26 
ExpB and confidence interval (CI) is included. According to the Omnibus test, the model was statistically significant (p=0.005). 
Hosmer–Lemersow test (p=0.96). R2 Nagelkerke (p=0.09). Statistically significant values are highlighted in bold. 
 
Supplementary Table 2H. Multiple Logistic Regression Model according to metastatic status of CRC patients at 
diagnosis time: FAP positive and high staining of Cyclin-D1 in local lymph node metastasis.  
 Local metastasis 
Variables p value B ExpB Inferior Superior 
Grade 0.75 -0.08 0.92 0.54 1.57 
pT 0.07 0.54 1.72 0.96 3.10 
N 0.36 0.28 1.32 0.73 2.41 
FAP(+)/Cyclin-D1 0.28 0.11 1.12 0.91 1.36 
ExpB and confidence interval (CI) is included. According to the Omnibus test, the model was not statistically significant 
(p=0.138). Hosmer–Lemersow test (p=0.5). R2 Nagelkerke (p=0.05). 
 
 
Supplementary Table 3. Log-rank test results of the association between FAP and BCAT, CD44 and Cyclin-D1, and 











Tumor Center 0.94 0.54 0.86 0.82 
Infiltrating front 3.3x10-4 0.001 0.024 0.033 
Local metastasis 0.07 0.07 5x10-4 5x10-4 
Distant metastasis 0.98 0.5 0.86 0.95 
FAP(+)/CD44 high      
Tumor Center 0.72 0.98 0.71 0.95 
Infiltrating front 0.34 0.47 0.22 0.46 
Local metastasis 0.39 0.17 0.06 0.06 
Distant metastasis 0.97 0.76 0.63 0.72 
FAP(+)/CyclinD1 high      
Tumor Center 0.5 0.83 0.84 0.81 
Infiltrating front 0.71 0.46 0.37 0.78 
Local metastasis 0.22 0.15 0.15 0.09 
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Supplementary Table 4A. Univariate analysis (Cox regression model) of clinical and pathological variables and 
FAP(+)/BCAT(N) expression in tumor front: analysis of 5-year CSS of AdC patients.  
Variables p value ExpB Inferior Superior 
Grade 0.012 1.441 1.085 1.915 
pT 1x10-6 2.021 1.528 2.673 
N 0.022 1.284 1.036 1.592 
M 1x10-6 2.161 1.596 2.927 
FAP(+) / BCAT(N) 
Tumor front 
4.9x10-4 1.189 1.079 1.311 
ExpB and confidence interval (CI) is included. Statistically significant values are highlighted in bold. 
 
Supplementary Table 4B. Univariate analysis (Cox regression model) of clinical and pathological variables and 
FAP(+)/BCAT(N) expression in tumor front: analysis of 10-year CSS of AdC patients.  
Variables p value ExpB Inferior Superior 
Grade 0.15 1.2 0.94 1.55 
pT 8x10-6 1.78 1.38 2.29 
N 0.15 1.15 0.95 1.38 
M 4x10-6 1.9 1.44 2.49 
FAP(+) / BCAT(N) 
Tumor front 
0.002 1.16 1.06 1.27 




Supplementary Table 5A. Univariate analysis (Cox regression model) of clinical and pathological variables and 
FAP(+)/BCAT(N) expression in tumor front and local lymph node metastasis: analysis of 5-year disease-free survival 
(DFS) of AdC patients.  
Variables p value ExpB Inferior Superior 
Grade 0.10 1.33 0.94 1.87 
pT 0.004 1.68 1.17 2.39 
N 0.09 1.25 0.96 1.62 
FAP(+) / BCAT(N) 
Tumor front 
0.028 1.15 1.01 1.31 
FAP(+) / BCAT(N) 
Local metastasis 
0.001 1.31 1.11 1.54 
ExpB with confidence interval (CI) is included. Statistically significant values are highlighted in bold. 
 
Supplementary Table 5B. Univariate analysis (Cox regression model) of clinical and pathological variables and 
FAP(+)/BCAT(N) expression in tumor front and local lymph node metastasis: analysis of 10-year disease-free survival 
(DFS) of AdC patients.  
Variables p value ExpB Inferior Superior 
Grade 0.38 1.15 0.84 1.57 
pT 0.02 1.48 1.06 2.07 
N 0.29 1.13 0.89 1.44 
FAP(+) / BCAT(N) 
Tumor front 
0.04 1.13 1 1.28 
FAP(+) / BCAT(N) 
Local metastasis 
0.001 1.31 1.11 1.54 
ExpB with confidence interval (CI) is included. Statistically significant values are highlighted in bold. 
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Supplementary Table 6A. Predictive model (Cox regression) for 10-year cancer-specific survival (CSS) prediction in 
AdC patients.  
  Tumor front 
10-year CSS Variables p value ExpB Inferior Superior 
pT 1x10-4 1.68 1.28 2.19 
M 0.001 1.64 1.24 2.17 
FAP(+)/BCAT(N) 0.003 1.15 1.05 1.26 
Selected independent variables were: FAP(+)/BCAT(N) expression in the primary tumor’s infiltrating front, local invasion (pT) 
and distant (M) metastases. ExpB with confidence interval (CI) is also included. Statistically significant values are highlighted 
in bold. 
 
Supplementary Table 6B. Predictive model (Cox regression) for 10-year disease-free survival (DFS) prediction in AdC 
patients.  
  Tumor front Local metastasis 
10-year DFS Variables p value ExpB Inferior Superior p value ExpB Inferior Superior 
pT 0.03 1.47 1.04 2.08 0.02 1.61 1.09 2.39 
FAP(+)/BCAT(N) 0.03 1.14 1.01 1.29 0.01 1.31 1.11 1.54 
Selected independent variables were: FAP(+)/BCAT(N) expression in the primary tumor’s infiltrating front and in lymph node 
metastasis, and local invasion (pT). ExpB with confidence interval (CI) is also included. Statistically significant values are 
highlighted in bold. 
 
Supplementary Table 7. Univariate analysis (Cox regression model) of clinical and pathological variables and 
plasmatic FAP levels for AdC patients’ 5-year overall survival prediction.  
Variables p value B ExpB Inferior Superior 
Grade 2.7x10-4 2.69 14.77 3.46 63.08 
pT 1.6x10-4 1.17 3.23 1.76 5.95 
N 0.001 0.76 2.13 1.38 3.28 
M 0.016 1.46 4.31 1.31 14.13 
V 3.4x10-4 1.32 3.73 1.82 7.67 
L 0.203 0.48 1.62 0.77 3.41 
Pn 3.9x10-4 1.23 3.43 1.74 6.79 
Soluble FAP 0.001 -1.34 0.26 0.11 0.59 
ExpB with confidence interval (CI) is also included. Statistically significant values are highlighted in bold 
 
 
